Dupilumab治疗重症哮喘的研究进展

Progress in the treatment of severe asthma with dupilumab

支气管哮喘(哮喘)是以2型辅助性T细胞(Th2)介导的炎症反应为主的慢性气道炎症性疾病。Th2细胞通过释放白细胞介素4(IL-4)、IL-13与共受体IL-4受体α亚基(IL-4Rα)结合,激活下游信号转导,导致哮喘气道炎症反应的发生。Dupilumab是全人源化的抗IL-4Rα单克隆抗体,能够与IL-4Rα高亲和力结合,从而竞争性抑制IL-4、IL-13与IL-4Rα结合,减少重症哮喘急性发作、改善肺功能。本文将对Dupilumab治疗重症哮喘患者的有效性和安全性研究进展进行综述。

Bronchial asthma(asthma)is such a chronic airway inflammatory disease which mediated by T helper cell type 2(Th2).The Th2 cells secret interleukin-4(IL-4)and IL-13,which activate the downstream signal transduction through the co-receptor interleukin-4 receptorα(IL-4Rα).Dupilumab is a fully human anti-IL-4 Rαmonoclonal antibody that competitive inhibits the combination between IL-4Rαand IL-4 or IL-13,which can reduce severe exacerbation and increased lung function in patients with severe asthma.The update of the efficacy and safety of dupilumab for treating severe asthma is reviewed in this article.